middle.news
Argenica Seeks FDA Meeting After New Pathway Emerges for Xaranetide
4:44pm on Thursday 19th of November, 2026 AEDT
•
Biotechnology
Read Story
Argenica Seeks FDA Meeting After New Pathway Emerges for Xaranetide
4:44pm on Thursday 19th of November, 2026 AEDT
Key Points
FDA maintains clinical hold on xaranetide IND
GLP rat study required to assess potential Olney lesions
Permitted exposure limit set below proposed Phase 2b doses
Argenica preparing a Type A FDA meeting
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Argenica Therapeutics (ASX:AGN)
OPEN ARTICLE